In the Face of the Epidemic Situation,ChemExpress Realize Work Resumption
The outbreak of pneumonia in Wuhan caused by new coronavirus (2019-nCoV) has been affecting the hearts of all sectors of the society. ChemExpress always pays close attention to the development of the epidemic situation, working together with the Chinese people to overcome the epidemic! The company fulfills its commitment to "assisting China's scientific research" and pays respects to frontline drug research and development researchers.
COVID-19 Special Situation Team
Since January 25, 2020 (3rd of lunar January),ChemExpress established a special situation team for the new epidemic. It actively maintained a high degree of closeness with domestic and foreign scientific research institutions, hospitals, pharmaceutical companies to help promote the anti-virus development. The company provided scientific research reagent, active small molecule compound, virtual library screening, building block screening and research and development; actively assisted pharmaceutical companies in the rapid clinical advancement of new antiviral drugs; coordinated the preparation of medical masks, medical protective clothing and other materials through different channels to support the government and front-line defense personnel to do a good job of protection.
Free sharing of our drug screening resources
ChemExpress donated virtual screening compound library resources and FDA-approved drug library to the research institutes that develop COVID-19 drugs, and fully supported the research and development of new coronavirus drugs.
ChemExpress provided inquiries and shipments of building blocks and reagents for enterprises and institutions that develop COVID-19-related drugs. We have sent kg-class pharmaceutical building blocks to research and development enterprises in Guangzhou.
Since January 26, 2020, we have realized the timely supply of small molecules required for the development of first-line COVID-19 drugs, and have continued to provide 7*24h technical and sales services.
On January 27, 2020, when we learned that Remdesivir had a better inhibitory effect on the virus, we established an emergency response team and provided scientific research samples of the compound to the relevant cooperative institutes of the Chinese Academy of Sciences to accelerate the development of virus inhibitory drugs. At the same time, we assisted pharmaceutical companies in the rapid clinical advancement of new antiviral drugs, provided a full range of technical support from raw materials to preparations, and promised to work overtime to help ensure timely and adequate supply of clinical samples.
We will continue to pay attention to the epidemic and work with all sectors of the community to overcome the difficulties.